How has the US market performed recently?

The US market dropped 2.5% over 7 days but rose 23% over the past year, with expected annual earnings growth of 17%.

Should I buy AbbVie stock based on this analysis?

The analysis does not provide a buy recommendation; it only suggests the stock may be undervalued. Further research and risk consideration are advised.

AbbVie (ABBV) Among 3 Stocks Possibly Undervalued in June 2026

With the US market dropping 2.5% over the past week yet rising 23% over the year, Simply Wall St identifies AbbVie (ABBV) as potentially undervalued, offering a possible opportunity for growth-focused investors.

June 8, 2026

2 min read

Source: Simply Wall St.

Key Numbers

us market drop 7d

2.5%

us market gain 1y

23%

expected earnings growth annual

17%

According to an analysis by Simply Wall St, AbbVie Inc. (ABBV) is among three stocks that may be trading below their estimated fair value in June 2026. This comes as the US market has declined 2.5% over the past seven days, but has risen 23% over the past year, with earnings expected to grow 17% annually in the coming years.

Details

The analysis by Simply Wall St used fundamental valuation metrics such as price-to-earnings (P/E) and price-to-book (P/B) ratios compared to industry and historical averages. The specific fair value for AbbVie was not disclosed, but the indication that it may be undervalued suggests a margin of safety for investors.

Context

AbbVie is a global biopharmaceutical company known for drugs like Humira and Skyrizi. The company faces challenges from patent expirations but is offsetting them with new product launches. In this context, a relatively low valuation could be an opportunity for investors betting on the company's ability to sustain earnings growth.

What This Means for Investors

While the analysis suggests AbbVie may be undervalued, investors should consider risks in the healthcare sector and competition. Further research and diversification are recommended before making any investment decisions.

Frequently Asked Questions

According to Simply Wall St, the list includes AbbVie (ABBV) along with two other stocks not disclosed in the analysis.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.